Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Remicade: A Study In Translational Looping

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.

You may also be interested in...

FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis

Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.

Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers

Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class

J&J Celebrates Simponi Approval With Schering – For Now

As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts